Cetera Advisor Networks LLC boosted its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 4.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,495 shares of the medical device company’s stock after buying an additional 1,180 shares during the quarter. Cetera Advisor Networks LLC’s holdings in DexCom were worth $3,790,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of DXCM. Avalon Trust Co acquired a new stake in DexCom in the first quarter valued at about $26,000. Atlas Capital Advisors LLC acquired a new stake in DexCom in the second quarter valued at about $33,000. TFC Financial Management Inc. boosted its stake in DexCom by 4,814.3% in the first quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock valued at $40,000 after buying an additional 337 shares in the last quarter. Valley National Advisers Inc. boosted its stake in DexCom by 33.5% in the second quarter. Valley National Advisers Inc. now owns 379 shares of the medical device company’s stock valued at $49,000 after buying an additional 95 shares in the last quarter. Finally, Center for Financial Planning Inc. acquired a new stake in shares of DexCom during the second quarter valued at about $51,000. 93.88% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other DexCom news, EVP Barry J. Regan sold 2,019 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total value of $192,249.18. Following the transaction, the executive vice president now owns 64,250 shares of the company’s stock, valued at $6,117,885. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Barry J. Regan sold 2,019 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $95.22, for a total transaction of $192,249.18. Following the transaction, the executive vice president now owns 64,250 shares of the company’s stock, valued at approximately $6,117,885. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bridgette P. Heller sold 600 shares of the company’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $106.56, for a total value of $63,936.00. Following the transaction, the director now directly owns 23,731 shares in the company, valued at approximately $2,528,775.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,908 shares of company stock valued at $657,820. Insiders own 0.41% of the company’s stock.
DexCom Stock Up 3.8 %
DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, October 26th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.16. DexCom had a return on equity of 25.05% and a net margin of 11.08%. The business had revenue of $975.00 million for the quarter, compared to analysts’ expectations of $939.64 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The business’s revenue was up 26.7% on a year-over-year basis. On average, sell-side analysts forecast that DexCom, Inc. will post 1.43 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on DXCM. UBS Group cut their price target on DexCom from $175.00 to $138.00 and set a “buy” rating on the stock in a research note on Wednesday, September 6th. TheStreet lowered DexCom from a “b-” rating to a “c+” rating in a research note on Wednesday, September 6th. Robert W. Baird lowered their price objective on DexCom from $153.00 to $130.00 and set an “outperform” rating for the company in a research report on Monday, August 21st. Barclays raised their price objective on DexCom from $115.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Monday, July 31st. Finally, Stifel Nicolaus lowered their price objective on DexCom from $155.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, October 10th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $130.93.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
- Five stocks we like better than DexCom
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Safeguard your portfolio with these three bargain stocks
- What is Put Option Volume?
- Membership clubs gain leverage for the consumer rebound
- Trading Stocks: RSI and Why it’s Useful
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.